Drug monitoring of etoposide (VP16-213)
- 1 August 1985
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 15 (2) , 121-124
- https://doi.org/10.1007/bf00257521
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Combined thin layer chromatography/mass spectrometry: An application of252Cf plasma desorption mass spectrometry for drug monitoringJournal of Mass Spectrometry, 1985
- Plasma assay for the antineoplastic agent VP 16-213 (etoposide) using high-performance liquid chromatography with electrochemical detectionJournal of Pharmaceutical and Biomedical Analysis, 1983
- The podophyllotoxin derivatives VP16-213 and VM26Cancer Chemotherapy and Pharmacology, 1982
- Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancerCancer Chemotherapy and Pharmacology, 1982
- Pharmacokinetics of VP16-213 given by different administration methodsCancer Chemotherapy and Pharmacology, 1982
- The clinical pharmacology of VM26 and VP16-213Cancer Chemotherapy and Pharmacology, 1982
- High-performance liquid chromatography determination of 4′-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene β-d-glucopyranoside) (VP 16-213) in human plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1981